---
title: "Gilead slips despite Q1 beats as it now expects 2026 loss per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285629987.md"
description: "Gilead Sciences (GILD) shares fell ~2% in after-hours trading despite Q1 results exceeding expectations. The company revised its 2026 non-GAAP EPS guidance to a loss of ($1.05)-($1.65), down from a prior estimate of $8.45-$8.85, due to $11.5B in IPR&D charges and financing costs. Gilead projects full-year product sales of $30B-$30.4B, aided by a 10% increase in HIV sales and significant growth in its breast cancer treatment, Trodelvy. As of March 31, Gilead's cash and equivalents stood at $8.6B, down from $10.6B at the end of 2025."
datetime: "2026-05-07T22:21:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285629987.md)
  - [en](https://longbridge.com/en/news/285629987.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285629987.md)
---

# Gilead slips despite Q1 beats as it now expects 2026 loss per share

Gilead Sciences (GILD) is down ~2% in after-hours trading Thursday despite Q1 results that beat on both lines as full-year non-GAAP EPS guidance was updated to a loss from earnings. The biotech giant now sees 2026 non-GAAP EPS of ($1.05)-($1.65) compared to $8.45-$8.85 prior. Consensus is $8.65. The company said the drastic change in EPS is due to ...

### Related Stocks

- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/286893590.md)
- [Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline](https://longbridge.com/en/news/286673327.md)
- [Gilead Sciences prices $3B multi-tranche senior notes offering](https://longbridge.com/en/news/286518399.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)